Skip to main content

Peer Review reports

From: Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis

Original Submission
2 Oct 2022 Submitted Original manuscript
11 Oct 2022 Author responded Author comments - Ruey-Long Hong
Resubmission - Version 2
11 Oct 2022 Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
22 Oct 2022 Reviewed Reviewer Report
30 Oct 2022 Reviewed Reviewer Report - Hui-ching Wang
11 Nov 2022 Author responded Author comments - Ruey-Long Hong
Resubmission - Version 5
11 Nov 2022 Submitted Manuscript version 5
16 Nov 2022 Reviewed Reviewer Report
20 Nov 2022 Reviewed Reviewer Report - Hui-ching Wang
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
21 Nov 2022 Editorially accepted
28 Nov 2022 Article published 10.1186/s12885-022-10343-7

You can find further information about peer review here.

Back to article page